Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $55.5MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ra Capital Management, L.p. | 10% Owner | Jun 16 '26 | Buy | $24.98 | 61,523 | $1,536,845 | 6,444,637 | Jun 17 06:24 PM |
| Ra Capital Management, L.p. | 10% Owner | Jun 15 '26 | Buy | $24.89 | 6,146 | $152,974 | 6,383,114 | Jun 17 06:24 PM |
| Ra Capital Management, L.p. | 10% Owner | May 19 '26 | Buy | $24.97 | 3,802 | $94,936 | 6,375,972 | May 21 04:20 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.